Cargando…
Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie's disease
INTRODUCTION: The aim of this study was to evaluate the combination of intralesional verapamil injection (IVI) therapy with and tadalafil in men affected by Peyronie's disease (PD). MATERIALS AND METHODS: In this study, 59 patients diagnosed with PD, were divided into three groups. Group A (GA)...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518372/ https://www.ncbi.nlm.nih.gov/pubmed/26229323 http://dx.doi.org/10.4103/0974-7796.152048 |
_version_ | 1782383339689213952 |
---|---|
author | Dell’Atti, Lucio |
author_facet | Dell’Atti, Lucio |
author_sort | Dell’Atti, Lucio |
collection | PubMed |
description | INTRODUCTION: The aim of this study was to evaluate the combination of intralesional verapamil injection (IVI) therapy with and tadalafil in men affected by Peyronie's disease (PD). MATERIALS AND METHODS: In this study, 59 patients diagnosed with PD, were divided into three groups. Group A (GA) counted 23 patients treated with IVI; Group B (GB) treated 19 patients with tadalafil 5 mg once a day, and Group C (GC) treated 17 patients with IVI and tadalafil for 3 months. There were assessed at baseline and follow-up: Erectile function, presence and severity of painful erections, penile plaque size and penile curvature degree. RESULTS: After 3 months pain resolved completely in 57% cases of GA, 61% of GB and 76% of GC; the final mean curvature degree further decreased in all groups without statistically significant differences; mean plaque size remained stable in GA: 1.57 versus 1.59 at baseline (P = 0.364) and GB: 1.51 versus 1.52 at baseline (P = 0,265), while a further decrease was evident in GC: 1.46 versus 1.58 at baseline (P = 0.03). Mean International Index of Erectile Function-5 score further improved significantly in the group treated with verapamil plus tadalafil: 23.1 versus 14.4 of GA and 18.2 of GB (P ≤ 0.01). CONCLUSIONS: The association of IVI and tadalafil showed better pain control while reducing penile curvature and erectile function, improving the quality of life. |
format | Online Article Text |
id | pubmed-4518372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-45183722015-07-30 Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie's disease Dell’Atti, Lucio Urol Ann Original Article INTRODUCTION: The aim of this study was to evaluate the combination of intralesional verapamil injection (IVI) therapy with and tadalafil in men affected by Peyronie's disease (PD). MATERIALS AND METHODS: In this study, 59 patients diagnosed with PD, were divided into three groups. Group A (GA) counted 23 patients treated with IVI; Group B (GB) treated 19 patients with tadalafil 5 mg once a day, and Group C (GC) treated 17 patients with IVI and tadalafil for 3 months. There were assessed at baseline and follow-up: Erectile function, presence and severity of painful erections, penile plaque size and penile curvature degree. RESULTS: After 3 months pain resolved completely in 57% cases of GA, 61% of GB and 76% of GC; the final mean curvature degree further decreased in all groups without statistically significant differences; mean plaque size remained stable in GA: 1.57 versus 1.59 at baseline (P = 0.364) and GB: 1.51 versus 1.52 at baseline (P = 0,265), while a further decrease was evident in GC: 1.46 versus 1.58 at baseline (P = 0.03). Mean International Index of Erectile Function-5 score further improved significantly in the group treated with verapamil plus tadalafil: 23.1 versus 14.4 of GA and 18.2 of GB (P ≤ 0.01). CONCLUSIONS: The association of IVI and tadalafil showed better pain control while reducing penile curvature and erectile function, improving the quality of life. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4518372/ /pubmed/26229323 http://dx.doi.org/10.4103/0974-7796.152048 Text en Copyright: © Urology Annals http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Dell’Atti, Lucio Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie's disease |
title | Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie's disease |
title_full | Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie's disease |
title_fullStr | Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie's disease |
title_full_unstemmed | Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie's disease |
title_short | Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie's disease |
title_sort | tadalafil once daily and intralesional verapamil injection: a new therapeutic direction in peyronie's disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518372/ https://www.ncbi.nlm.nih.gov/pubmed/26229323 http://dx.doi.org/10.4103/0974-7796.152048 |
work_keys_str_mv | AT dellattilucio tadalafiloncedailyandintralesionalverapamilinjectionanewtherapeuticdirectioninpeyroniesdisease |